SBIR/STTR Research Award

Broad Spectrum Antidotes against Superantigen Toxins

Award identifier 707cffb23b654883ea21774108e49e2db0be673299c58964095aef4a5a4e78c7Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$600,000

Program and phase

SBIR · Phase I

Award year

2010

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Sonitu Pharmaceutical, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2010-2
Topic code
NIAID

Research abstract

DESCRIPTION (provided by applicant): Staphylococcal Enterotoxin B (SEB), Streptococcal Pyogenes Enterotoxin C (SPEC) and Toxic Shock Syndrome Toxin-1 (TSST-1) are among the highly incapacitating superantigen (sAg) toxins that are known to cause the incapacitating toxic shock syndrome (TSS) in human. Thus, these toxins can potentially be used in a bioterrorism attack. There is a medical need to develop broad-spectrum antibodies that can effectively be used as countermeasures. Preventing the binding of sAg toxins to the major histocompatibility complex class II (MHC-II) molecules by antagonist peptides and/or by antibodies might be an effective approach to develop such countermeasures. We have identified antagonist peptides, derived from the highly conserved domains from the sAg family of toxins. These peptides neutralized actions of SEB, SPEC and TSST-1 by preventing their binding to MHC-II molecules. Two of these peptides rendered broad-spectrum protection to mice and rabbits that were challenged with sAg toxins. More importantly, the polyclonal antibodies (pAbs) prepared against one of these peptides specifically recognized a number of sAg toxins and also neutralized their toxicities in animal models. Although the monoclonal antibodies (mAbs) against the antagonist peptide showed broad-spectrum binding to sAg toxins, but they provided only partial protection (30 to 40%) to mice challenged with SEA, raising the possibility that a single mAb might not be sufficient for the Fc-mediated rapid clearance of the toxin molecules from the body. Thus, combination of 2-3 high affinity mAbs, recognizing non-overlapping epitopes, might be necessary to provide complete and rapid protection against these toxins. Based on these studies, we have developed a novel strategy to prepare high affinity mAbs recognizing highly conserved and non-overlapping epitopes such that they can be combined to decorate toxin molecule surface at different sites for the rapid Fc-mediated clearance. Two antagonist peptides were conjugated using a meleimidepropyl ester and the conjugated peptides (c-peptides) were biotinylated. The biotinylated c-peptides were mixed with avidin at a 4:1 ratio to facilitate formation of the tetrameric c- peptides. The tetrameric antigen elicited outstanding titer of high affinity pAbs in rabbits and the generated pAbs showed broad-spectrum binding to numerous sAgs toxins on native as well as on the denaturing blots. Thus, the same tetrameric peptides antigen may also be used to immunize mice to produce mAbs. The pAbs and mAbs will be evaluated in in vitro assays and in animal models for their neutralizing efficacies. Thus, successful completion of the proposed research will lead to not only produce effective pAbs and mAbs, but also validate the utility of the c-peptides as a potential candidate for vaccination and also for intravenous immunoglobulin (IVIG) therapy. PUBLIC HEALTH RELEVANCE: Staphylococcal Enterotoxin B (SEB), Streptococcal Pyogenes Enterotoxin C (SPEC) and Toxic Shock Syndrome Toxin-1 (TSST-1) are highly incapacitating superantigen (sAg) toxins, which are known to cause toxic shock syndrome (TSS) in human. Thus, there is an unmet need to develop broad-spectrum antibodies that can be effectively used for protection against these toxins. This grant proposal is to develop high affinity polyclonal and monoclonal antibodies that can be used as broad-spectrum antidotes against sAg toxins. The proposed research will also validate a novel approach to use the avidin/biotin- tetrameric peptides formulation as an antigen to produce antibodies against small peptides, and also validate its utility as a potential candidate for vaccination and/or for intravenous immunoglobulin (IVIG) therapy.

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.